5:59 PM · 11 October 2022

Amgen surges after Morgan Stanley upgrade

Amgen (AMGN.US) stock surged more than 6.0% after Morgan Stanley upgraded the biopharma company to overweight from equal weight, saying Amgen is “largely de risked” and provides defensiveness for investors.

Analysts believe the market is not appreciating upside potential that stems from the potential of obesity candidate AMG133, which could differentiate itself against others in the competitive obesity market through better weight loss, improved dosing frequency, and better tolerability.

Amgen (AMGN.US) stock rose sharply on Tuesday and managed to break above local resistance at $244.50, which coincides with 23.6% Fibonacci retracement of the last upward wave. Nevertheless, upward move was halted at the upper limit of the triangle formation and as long as price sits below, another downward impulse may be launched. Source: xStation5

7 August 2026, 5:45 PM

Who Will Surprise With Earnings Next Week? (07.08.2026)

7 August 2026, 3:07 PM

US OPEN: Shallow rebound in the shadow of a weak labor market

7 August 2026, 12:28 PM

Dollar and Nasdaq facing a key test

7 August 2026, 12:22 PM

Market Wrap: Tech lifts Europe to new record highs! Metals keep rallying despite stagnant USD (07.08.2026)

The financial instruments we offer, especially CFDs, can be highly risky. Fractional Shares (FS) is an acquired from XTB fiduciary right to fractional parts of stocks and ETFs. FS are not a separate financial instrument. The limited corporate rights are associated with FS.
This page was not created for investors residing in Brazil. This brokerage is not authorized by the Comissão de Valores Mobiliários (CVM) or the Brazilian Central Bank (BCB). The content of this page should not be characterized as an investment offer in Brazil or for investors residing in that country.
Losses can exceed deposits